07.01.2013 Views

2005 - Molex

2005 - Molex

2005 - Molex

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

these reasons, over the past few years,<br />

our strategy has been to consolidate<br />

multiple plants of modest size in fa-<br />

vor of operating fewer, larger and fully<br />

integrated facilities in strategic locations<br />

around the world.<br />

In <strong>2005</strong>, we began closing certain<br />

facilities in the U.S. and Europe and<br />

transferring production to existing plants<br />

within the same regions. Specifically, we<br />

will cease manufacturing in our Detroit<br />

automotive facility, but will keep the<br />

development center open. We also are<br />

closing an industrial products plant in<br />

New England. Additionally, we are clos-<br />

ing facilities in Ireland and Portugal and<br />

reducing the size of our development<br />

center in Germany.<br />

<strong>Molex</strong> was one of the first companies<br />

in our industry to manufacture in the<br />

Far East. Today, we operate six plants in<br />

China, including our Shanghai factory,<br />

which is undergoing a second expansion<br />

for a total of more than half a million<br />

square feet. When our seventh China<br />

factory opens in 2007, it will contain<br />

nearly 700,000 square feet and be our<br />

largest plant worldwide. Now, 40% of<br />

Return on Beginning<br />

Stockholders’ Equity<br />

7 . 5 %<br />

9 . 3 %<br />

<strong>Molex</strong> <strong>2005</strong> Annual Report<br />

T O O U R S H A R E H O L D E R S<br />

4 . 6 %<br />

4 . 3 %<br />

1 2 . 0 %<br />

05 04 03 02 01<br />

5<br />

our manufacturing capacity is in lower-<br />

cost areas such as China, Eastern Europe<br />

and Mexico.<br />

Investing in new products. Our new<br />

products not only boost sales and ensure<br />

our future, they also command the<br />

highest profit margins. In fiscal <strong>2005</strong>,<br />

we commercialized 384 products; that’s<br />

an average of more than one per day.<br />

We also were granted a record 775 patents<br />

worldwide. New releases–products intro-<br />

duced in the past three years–accounted<br />

for 30% of fiscal <strong>2005</strong> revenue. We intend<br />

to continue our industry-leading rate of<br />

investment in research and development<br />

to maintain that level in the year ahead.<br />

Reducing SG&A. Although our selling,<br />

general and administrative expense has<br />

improved, we believe that at more than<br />

24% of sales, it is still too high. As we<br />

continue to streamline our organization,<br />

our target is to become more efficient<br />

and cost effective and drive down our<br />

SG&A rate steadily over time.<br />

In all our operations, we are using<br />

the <strong>Molex</strong> Global Information System<br />

Capital Expenditures<br />

(in thousands of dollars)<br />

$ 2 3 0 , 8 9 5<br />

$ 1 8 9 , 7 2 4<br />

$ 1 7 1 , 1 9 3<br />

$ 1 7 2 , 4 9 7<br />

$ 3 7 6 , 3 0 0<br />

05 04 03 02 01

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!